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PCR-RFLPBackground: The signalling pathway Fas and FasL system plays a fundamental role in the regulation of
apoptotic cell death and any disturbance of this pathway has been shown to promote immune escape
and tumorigenesis. Many types of cancers show reduced expression of FAS and elevated FasL expression.
The Fas21377G/A, and FasL2844T/C polymorphismsmight be associatedwith increased risk of lung cancer.
Objective: The interplay between genetic polymorphisms could participate in cancer development. This
study aimed to examine the contribution of Fas21377AA and FasL2844CC genotypes to risk of developing
lung cancer.
Subjects and methods: A case-control study was conducted on 20 non small cell lung cancer (NSCLC) cases
and 40 controls. Genotyping of Fas 21377AA and FasL 2844CC Single nucleotide polymorphisms (SNPs) by
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)were done to all subjects.
Results: The distribution of Fas and FasL genotypes showed a higher frequency of Fas AA genotype among
patients compared to controls with an increased risk of lung cancer (OR 5.28; CI:1.35–20.65, P value .01).
No statistically significant difference was found between patients and controls groups in respect to FasL
genotypes. Gene to gene interaction between Fas and FasL genotypes showed significant differences
between the patients and controls groups. As regards the combination between FasL TT+CT & Fas AA, FasL
CC & Fas GG+GA and FasL CC & Fas AA genotypes where patients carrying FasL CC or Fas AA genotypes have
increased risk to develop lung cancer, (OR 10.28, 95% CI; 1.68–62.74, P value .01), (OR 72, 95% CI; 5.55–
132.99, P value .001) and (OR 9, 95% CI; 1.5–53.86, P value .01) respectively. The FasL-CC genotype showed
2.25 folds increased risk to develop lung cancer in non-smoker patients, P = .008. No correlation was found
between the pathological types, the stage of lung cancer and the Fas and FasL genotypes.
Conclusion: The interactionof the cell deathpathwaygenesFas andFasLpolymorphismscouldbeassociated
with the risk of lung cancer, in the same respect Fas AA genotype could also potentiate this risk.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is claimed to be one of the leading causes of cancer
related deaths over the world [1]. Since 1985, it has been the most
common cancer diagnosed each year [2]. Respiratory system
primary malignant tumors represent the fifth common tumors in
the Egyptian registry material, being about 5.9% of the total
malignancies [3].
Tumour evolution is a complex process with many interplaying
mechanisms and factors, among these is apoptosis (programmed
cell death). Disabling of apoptotic responses might be a crucialcontributor not only of tumour cell survival but also the resistance
to the anticancer therapy. Initiation of apoptosis is mainly depen-
dant on the Fas–Fas ligand (FasL) pathway [4]. Any disequilibrium
in the genes regulating this cell death pathway might lead to
cancer formation and development eg. single nucleotide
polymorphisms (SNPs) [5].
The Fas/FasL has been shown to influence cancer development
through two opposite effects where Fas expression with functional
signalling pathway trigger Fas mediated tumour cell killing by
effector cells, meanwhile FasL expression on tumour cells could
repel specific antitumour immune response turning tumour into
an immune privileged sites [6].
The genes of Fas & FasL are located on chromosome 1 (10q24.1
and regions 23, respectively). Fas gene encodes for transmembrane
protein I (319 amino acid residues) while FasL encodes for
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tion to the proappoptotic property of Fas/FasL signaling pathway,
several evidences demonstrated that this pathway can also acti-
vate many nonappoptotic pathways whose activation result in
increased tumourigenicity. Decreased expression of Fas and/or
increased expression of FasL are announced to be allied with differ-
ent malignancies and may also favor malignant conversion and
progression [5].
The Fas and FasL gene mutations that attenuated this apoptotic
signal transduction have been declared to display an augmented
threat to many cancer diseases. Numerous studies have declared
the linkage between Fas/FasL polymorphisms and risk of breast
cancer [9,10], gastric cancer [11,12], cervical cancer [13,14], eso-
phageal cancer [15,16] and lung cancer [17,18]. Moreover, the
impact of Fas and FasL polymorphisms on the increased risk of
oesophageal squamous cell carcinoma (SCC) displayed a multi-
plicative gene–gene interaction and appeared to be associate with
tobacco smoking [16]. Among candidate lung tumour progression
(LTP) genes, FasL was claimed to be the most important gene
whose expression changes may seriously influence lung tumour
progression in mice [19]. Furthermore, the Fas/FasL system may
have a considerable role in cancer beginning and prognosis. There-
fore, SNPs which acquire the potential to change the expression of
these genes have been anticipated to be crucial in the genetic
propensity to cancer [4].2. Objective
This work is an attempt to find an answer to a question why not
all subjects exposed to tobacco smoking or indoor air pollution
develop lung cancer? A search for genetic predisposition impli-
cated in the development of lung cancer have been created to find
the contribution of Fas 2377AA and FasL 2844CC polymorphisms to
the risk of lung cancer.
2.1. DNA extraction
Genomic DNA was extracted from blood samples obtained from
40 controls and 20 lung cancer patients using QIAamp DNA extrac-
tion kit (Qiagen Hilden, Germany, Cat No. 51304) according to the
manufacturer’s instructions.
2.2. Genotyping of Fas 21377AA and FasL 2844CC SNPs by PCR-RFLP
All patients and controls were genotyped using PCR based
restriction fragment length polymorphism (PCR-RFLP) methods
as described previously [15]. The PCR primers for amplification of
the Fas promoter region containing 21377G/A were 59-
TGTGTGCACAAGGCTGGCGC and 59-TGCATCTGTCACTGCACTT
ACCACCA, which produce a 122 bp fragment. In order to induce a
restriction endonuclease site, we changed the 39 end of the reverse
primer from CAC to CGC, which created a BstuI cutting site. For
amplification of the FasL promoter region containing 2844T/C site,
we used the primer pair of 59-CAGCTACTCGGAGGCCAAG and
59-GCTCTGAGGGGAGAGACCAT, which generates a 401 bp frag-
ment. Amplification of these two DNA fragments was accom-
plished separately under the same conditions, in a 25 ml reaction
mixture consisting of, 100 ng template DNA, 0.5 mmol/l each pri-
mer, 0.2 mmol/l dNTP, 2.0 mmol/l MgCl2, and 1.0 U of Taq DNA
polymerase with 16 reaction buffer (Promega, Madison, WI, USA).
The reaction was carried out in the following conditions: an initial
melting step of 2 min at 94 C, followed by 35 cycles of 30 s at
94 C, 30 s at 62 C, and 45 s at 72 C, and a final elongation step
of 7 min at 72 C. The restriction enzymes BstuI and BsrDI
(New England Biolabs Inc., Beverly, MA, USA) were used todistinguish the Fas 21377G/A and FasL 2844T/C polymorphisms,
respectively. The restriction products were separated on 2.5% agar-
ose gel with ethidium bromide. The RFLPs of the two polymor-
phisms were readily discerned. After digestion with BstuI, the Fas
21377G allele generated 104 bp and 18 bp fragments whereas
the variant 21377A allele generated a single 122 bp fragment.
The FasL 2844C allele had a BsrDI restriction site that resulted in
two bands (233 bp and 168 bp), and the 2844T allele lacked the
BsrDI restriction site, producing a single 401 bp band [17].
2.3. Statistical analysis
All analyses were done using SPSS Statistics version 17 ((SPSS
Inc., Chicago, IL). Pearson’s x2 test was used to compare differences
in Categorical variables between patients and controls. The associ-
ations between the polymorphisms and risk of increasing lung can-
cer were expected by odds ratios (ORs) and their 95% confidence
intervals (CIs), which were measured by logistic regression. Light
and heavy smokers were classified by median pack year value of
20 for heavy smokers. All ORs were adjusted for age, sex, and
smoking status or pack years, as possible. All statistical tests were
two sided tests. The null hypotheses of additive and multiplicative
gene–gene interaction was studied, then we assessed the deser-
tions from additive and multiplicative interaction models by
counting main effect variables and their outcome terms in the
logistic regression model.3. Subjects and methods
The work was a collaboration between National Cancer Institute
(NCI) and National Research Center (NRC), Cairo, Egypt. A case–
control study was conducted on 20 unrelated adult patients with
primary lung cancer and 20 smokers and 20 non-smokers unre-
lated controls. All subjects included in the study were interviewed
to fill a medical questionnaire with special consideration to the
lifetime history of tobacco use, residence, occupational history
and family history of cancer. Thorough clinical examination and
chest radiography were applied. Blood sample was obtained from
each subject for Genotyping of Fas 21377AA and FasL 2844CC SNPs
by PCR-RFLP. Sample for histopathology examination of cancer was
obtained from each patient either by open biopsy or via bron-
choscopy. The exclusion criteria included previous history of can-
cer, metastasized cancer from other organs, patients with
pulmonary fibrosis, acute interstitial pneumonia and previous
radiotherapy or chemotherapy or receiving any anti-cancer treat-
ment before enrollment in the study. The study was approved by
the ethics committee of the National Research Center. The work
has been carried out in accordance with the code of Ethics of the
World Medical association (Declaration of Helsinki) for experi-
ments in humans. All subjects were aware by the nature of the
study and gave a written informed consent.4. Results
The distribution of patients and controls characteristics were
demonstrated in Table 1 and showed that both groups were
matched as regards their sex. There was a statistically significant
difference between the two groups in concern to the number of
the smoked packs per year where all the smoking patients take
more than 20 packs per year (P value < .05).
The distribution of Fas and FasL genotypes frequencies among
patients and controls and their associations with the risk of lung
cancer were demonstrated in Table 2 and showed that the fre-
quency of Fas AA genotype was higher among the patient group
in comparison to the control group and those carriers of this
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20.65, P value .01). Upon adjustment of this comparison as regards
the sex, smoking history and the smoked packs per year, both Fas
AA & GA genotype frequencies demonstrated statistically signifi-
cant differences between the two groups and the carriers of these
genotypes have increased risk of lung cancer (OR 10; CI: 2.0–50.23,
P value .005) & (OR 41.48; CI: 1.04–164.1, P value .04) respectively.
On the other hand no statistically significant differences between
patient and control groups in respect to FasL genotypes.
The combined effect of Fas and FasL genotypes on the risk of the
lung cancer among patients and controls was demonstrated in
Table 3 and showed significant differences between the patient
and control groups as regards the combination between FasL TT
+CT & Fas AA, FasL CC & FAS GG+GA and FasL CC & Fas AA geno-
types where patients carrying either FasL CC or Fas AA genotypes
have increased risk to develop lung cancer (OR 10.28, 95% CI;
1.68–62.74, P value .01), (OR 72, 95% CI; 5.55–132.99, P value
.001) and (OR 9, 95% CI; 1.50–53.86, P value .01) respectively.
The Risk association of Lung cancer in relation to Fas and FasL
genotypes with smoking history and clinical characteristics of
patients was demonstrated in Table 4 and showed that the non
smoking patients having the FasL-CC genotype have 2.25 folds
increased risk to develop lung cancer (OR 2.25; CI: 1.08–4.67,Table 1
Distribution of patients and controls characteristics.
Patients Controls P-value ***OR (95% CI)
(n = 20) (n = 40)
No % No %
Gender .17 0.4 (0.1–1.5)
Male 14 70 34 85
Female 6 30 6 15
Smoking
Non-Smokers 9 45 20 50
Smokers 11 55 20 50 .72 1.2 (0.4–3.6)
Pack/year (n = 11) (n = 20)
<20 0 0 11 55









* Squamous cell carcinoma (SCC).











No. % No. % Crude
Fas
AA 13 32.5 14 70 5.28 (
GA 1 2.5 2 10 9.48 (
GG 26 65 4 20 1 (refe
FasL
CC 10 25 11 55 2.32 (
CT 3 7.5 2 10 1.83 (
TT 27 67.5 7 35 1 (refe
P-value < .05 is statistically significant.*Odd’s ratio.P value .008). No correlation was found between the pathological
types of lung cancer nor the stages and the Fas and FasL genotypes.5. Discussion
Single-nucleotide polymorphisms (SNPs) have been recognized
in the promoter region of the Fas gene, A or G at position-670
(Fas-670A/G) and G or A at position-1377 (Fas-1377G/A). Reduced
promotor activity and paucity of Fas gene expression represent a
consequence of the disruption of TAT1 and Sp1 transcription
factor-binding sites by Fas-670G allele and the Fas-21377A allele
respectively [20,21]. Regarding functional SNPs of FasL promoter
activity, T or C at position 2844 (FasL2844T/C) have been demon-
strated, where the FasL2844 C allele is significantly linked with
higher basal expression of FasL than the FasL2844 T allele [22].
The Fas21377G/A, and FasL2844T/C polymorphisms might be
allied with the increased risk of lung cancer.
In the present study, the frequency of the homozygous mutant
allele Fas-AA was higher among the patient group compared to
control and showed 5.28 folds increased risk of lung cancer. Upon
adjustment of this comparison as regards the sex, smoking history
and the smoked packs per year, both Fas AA & GA genotypes
demonstrated statistically significant differences between the
two groups where the carriers of these genotypes have 10 and 41
folds increased risk of lung cancer, respectively. Meanwhile, FasL
genotypes did not differ significantly between patient and control
groups. In agreement with ours, Zhang et al. (2005) demonstrated
that carriers of the Fas 21377AA genotype have increased risk of
lung cancer by 1.6 folds [18]. Also, Park et al. (2006) and Sung
et al. (2011) reported that the FasL 2844T/C genotype was not
linked with increased lung cancer risk [17,23].
Gene-gene interaction was implicated in this study in order to
highlight the role of FasL2844T/C gene polymorphism. The combi-
nation of the homozygous mutant alleles FasL CC with the
homozygous Fas AA mutant alleles or either the wild GG allele
and heterozygous GA were more frequent in patients (30% and
25% respectively) compared to that in control (20% and 5% respec-
tively) and demonstrating 9 and 72 folds increased risk to develop
lung cancer. Similarly, the combination of the homozygous Fas AA
with the wild and heterozygous FasL TT, CT was more frequent in
patients (40%) compared to that in control (12.5%) increasing the
risk of lung cancer by 10.28 folds. These findings were in accor-
dance with Zhang et al. (2005) where they assumed that patients
with the FasL 2844CC genotype have more chance to carry Fas
21377AA than the controls were, but with only 4.18 folds increased
risk to develop lung cancer [18]. Similarly, numerous studies
announced that subjects carrying both Fas 21377AA and FasL
2844CC could be at higher threat for acquiring lung cancer than
those carrying either the Fas 21377AA or FasL 2844CC alone






1.35–20.65) 0.01 10 (2.0–50.23) 0.005
0.63–141.8) 0.1 41.48 (1.04–164.1) 0.04
rence) – 1 (reference) –
0.61–8.74) 0.2 1.67 (0.37–7.42) 0.49
0.21–15.4) 0.5 2.38 (0.22–24.82) 0.46
rence) – 1 (reference) –
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TT+CT AA 8 (40%) 5 (12.5%) 10.28(1.68–62.74) .01
CC GG
+GA
5 (25%) 2 (5%) 72 (5.55–132.99) .001
CC AA 6 (30%) 8 (20%) 9 (1.50–53.86) .01
P-value < .05 is statistically significant.
* Odd’s ratio.
Table 4
Risk association of Lung cancer in relation to Fas and FasL genotypes with smoking history and clinical characteristics of patients.














OR_(95% CI) p value
Smoking status
Nonsmoker (7/8) (2/12) 0.5 (0.068–3.67) .64 (4/3) (5/17) 2.25 (1.08–4.67) .008
Smoker (7/5) (4/15) 0.5 (0.13–1.93) .5 (11/3) (0/17) 1 (0.17–5.67) 1
Pack years smoked
<20 (0/7) (0/4) (0/5) (0/6)
 20 (7/3) (4/6) 0.44(0.05–3.5) .61 (6/2) (5/7) 0.35 (0.02–4.65) .56
Histological type
SCC* (6/–) (2/–) .1 (5/–) (3/–) .2
Adenocarcinoma (5/–) (0/–) (1/–) (4/–)
Other_ (3/–) (4/–) (5/–) (2/–)
Stages
II (1/–) (3/–) .06 (2/–) (2/–) .4
III (9/–) (1/–) (8/–) (2/–)
IV (4/–) (2/–) (5/–) (1/–)
* Squamous cell carcinoma (SCC). P-value < .05 is statistically significant. *Odd’s ratio.
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mode. The altered cells with high level of FasL as a result of the
FasL 2844CC genotype expression may evade host immune surveil-
lance either by creating an immune privileged site and/or killing
cytotoxic immune cells [18].
Tobacco smoking is a conventional, widely known causal factor
for lung cancer. In this study it was found to be prevalent by 1.2
times more among smokers than among the non-smokers and to
be 2.2 times more risky in heavy smokers (20 pack/year) than
in light smokers (<20 pack/year). Gene–environment interaction
of Fas or FasL polymorphisms and smoking coupled with increased
risk of lung cancer was found in several studies. Although our
study did not demonstrate significant difference regarding FAS
gene polymorphisms and smoking, yet Zang et al. (2005)
announced that the risk of lung cancer was altered among smokers
carrying Fas 21377AA genotype, while among the non smokers
with the same genotype was not; signifying a gene–environment
interaction. However, this involvement was higher in light than
in heavy smokers where tobacco carcinogens are giving rise to
transformed or pre-invasive lung cells and when coupled with
either low Fas expression and/or increased FasL, one of these cells
will evade immune surveillance to become carcinogenic [18]. For
the FasL polymorphism, in this study the increased risk to develop
lung cancer by 2.25 folds was demonstrated among non-smokers
carrying the FasL-CC genotype. Also, Zhao et al. (2016) observed
that the risk of lung cancer was increased significantly among both
smokers and non-smokers with more pronounced increase among
heavy smokers than light smokers [29]. Moreover, because tobaccosmoking can provoke FasL expression Suzuki et al. (1999) and Bijl
et al. (2001) stated another hypothesis for this relation, where the
level of FasL expression from the FasL 2844C allele was higher than
that from the FasL 2844T allele upon induction by smoking and in
addition to the higher constitutive expression resulting from the
FasL 2844T/C polymorphism, smoking and FasL 2844CC genotype
increase vulnerability of lung cancer [30,31]. Zhang et al. (2005)
stated that the high level of environmental smoke that non-
smokers exposed to throughout ordinary life may justify the higher
risk of lung cancer among non smokers carrying FasL 2844CC geno-
type when compared with those carrying the same genotype and
smoked less than 20 packs per year [18].
The results comparing lung cancer vulnerability with the Fas
and FasL polymorphisms among different subtypes and stages of
lung cancer were controversial. In this study, neither the histolog-
ical type of lung cancer nor its stage have an impact on the risk of
developing lung cancer when correlated with 21377AA genotype
or FasL 2844CC genotype. Similar findings were declared by Zhang
et al. (2005) when correlating the risk of lung cancer with Fas
21377AA or FasL 2844CC genotypes and histological types of lung
cancer [18]. Conversely, Zhao et al. (2015) & (2016) found that,
FasL 2844 and Fas 21377 SNPs were linked with increased vulner-
ability of pulmonary adenocarcinoma (AD) [5] and FasL 2844CC
was found to be a risk factor for pulmonary SCC [29]. Though Sung
et al. (2011) did not find that FasL 2844 polymorphism increased
the risk of lung cancer, they found that FasL 2844CC genotype
had higher incidence in those with advanced tumors than in those
with early tumors, also FasL 2844CC was found to be a risk factor
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This may support the possibility that pulmonary SCC with FasL
2844CC has a stronger invasion [29]. Findings related to the
genes-smoking interaction, the histopathological types and the
stage of lung cancer were not always consistent with one another,
partially because of dissimilarity in sample sizes and cultural
backgrounds.
In conclusion, this study provides the substantiation that func-
tional Fas and FasL polymorphisms are associated with the
increased risk of lung cancer and exhibit a gene–gene interaction.
The FasL polymorphism increases the risk of lung cancer in non-
smokers.
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